Skip to content

Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD)

Removal of Ligand-bound Iron During Intravenous Iron Administration in Hemodialysis by Large Pore Dialyzers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00638300
Enrollment
25
Registered
2008-03-19
Start date
2008-03-31
Completion date
2010-07-31
Last updated
2010-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis Patients

Keywords

hemodialysis, iron, inflammation, atomic absorption, dialysate, advanced oxidation protein products, large pore dialysate, bicarbonate, calcium, citrate, ligand

Brief summary

The study's hypothesis is that HD with large pore dialyzers remove to the dialysate iron which is bound to potentially dialyzable ligands, after it's release from intravenous iron compound administered during hemodialysis.

Detailed description

Most hemodialysis(HD) patients receive during HD intravenous iron compounds, which are composed of an iron core and a sugar polymer shell. A small percentage of iron from the iron compound is released to the plasma, and may be associated with increased oxidative stress and protein oxidation. The study's hypothesis is that HD with large pore dialyzers may remove to the dialysate iron which is bound to potentially dialyzable ligands, after it's release from intravenous iron compound administered during hemodialysis. Ligand-bound iron removal is also hypothesized to be affected by dialysate calcium and bicarbonate concentrations, which may affect iron-ligand binding. Study Specific aims are: To evaluate 1. Iron removal assessing dialysate iron levels. 2. Effect of iron removal and it's associated experimental conditions on patient status, assessing plasma AOPP levels and inflammation related parameters Study include 3 parts 1. Comparing large to small pore dialyzers (To achieve baseline uniform conditions, patients will be on uniform dialysate bicarbonate and calcium concentrations of 33 mEq/L and 3 mEq/L,respectively, using large pore dialyzers during this part, besides the 2 HD sessions evaluating low pore dialyzers) and after few week break Using large pore dialyzers to compare 2. Low to high dialysate bicarbonate concentration (using uniform dialysate calcium concentrations of 3 mEq/L) and after few week break 3. Low to high dialysate calcium concentrations concentration (using uniform dialysate bicarbonate of 33 mEq/L) In each part, patients will be first evaluated in HD without IV iron administration, which will serve as a control for evaluation after a week in HD with IV iron administration. In each part, patients will be randomized to start either with one of the 2 experimental conditions, and after 1 week without evaluation will cross-over to the other experimental condition. Patients may participate in 1,2 or the 3 parts of study depending on their will and condition.

Interventions

DEVICElarge pore (FX80) compared to small pore dialyzer (F8HPS)

Effect of pore size

OTHERDialysate bicarbonate of 33 mEq/L compared to 40 mEq/L

Effect of dialysate bicarbonate concentration

OTHERDialysate calcium of 3 mEq/L compared to 2.5 mEq/L

Effect of dialysate calcium concentration

Sponsors

Bnai Zion Medical Center
CollaboratorOTHER_GOV
Rivka Ziv Medical Center
CollaboratorUNKNOWN
Soroka University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 88 Years
Healthy volunteers
No

Inclusion criteria

* Chronic hemodialysis patients

Exclusion criteria

* Acute disease (infection, thrombosis, ischemia, bleeding) Hepatitis B, Hepatitis C or HIV * Intravenous iron administration or packed red cell transfusion in the last 3 weeks prior to the study * Refusal to comply with limitations in fat containing food during HD with plasma sampling for AOPP evaluation

Design outcomes

Primary

MeasureTime frame
1. Dialysate Iron levels 2. Plasma levels of advanced oxidation protein products(AOPP)Before HD, after 1 hour of HD with or without IV iron and at end of HD

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026